Research Use Only - Not for human consumption. 18+ only.
BGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use onlyMuscle Growth & PerformanceIntravenousSubcutaneous

ACE-031

A soluble activin receptor type IIB (ActRIIB) fusion protein that functions as a myostatin and activin A trap. Developed for treatment of muscle wasting diseases, including muscular dystrophy and cachexia. Acts by sequestering myostatin and activin A, negative regulators of muscle growth.

Beginner Basics

Plain-English guide to ACE-031

What it does

ACE-031 blocks two chemicals that limit muscle growth, allowing muscles to build larger and stronger. Researchers studied it for conditions where muscles waste away, but development was paused due to safety concerns.

Typical dose

Research doses ranged from 1-3 mg per kilogram of body weight, given every two weeks through injection into a vein or under the skin.

When to inject

In research settings, timing was flexible since it was given every two weeks. Healthcare providers supervised all administration.

Storage

Keep the dry powder in a freezer at -20°C. Once mixed with liquid, store in a regular refrigerator at 36-46°F for up to 14 days. Keep it away from light and throw it away if it looks cloudy or discolored.

First-timer tip

This compound is not approved for human use outside controlled research-it was halted in development due to safety signals. Do not use without medical supervision in an official trial.

Research Status

BGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only

Limited Clinical Data

For research purposes only. Not approved for human use. Not medical advice.

Research Areas

Increases skeletal muscle mass and strength
Reduces muscle wasting in dystrophic conditions
Improves muscle regeneration capacity
Enhances exercise tolerance
Reduces circulating myostatin levels

Side Effects

Polycythemia (elevated hemoglobin/hematocrit)
CommonModerate

Observed in clinical trials. Likely due to activin A inhibition, which normally suppresses hepcidin and iron metabolism. Requires regular hematologic monitoring. May increase thrombotic risk if severe.

Dorsal root ganglion (DRG) toxicity
UncommonSerious

Observed in animal studies at high doses. Manifested as sensory neuropathy and neuronal degeneration. Human incidence unclear; clinical trials were paused partly due to this signal. Requires neurological assessment if symptoms develop.

Injection site reactions
UncommonMild

Erythema, induration, or mild pain at injection site. Typical of SC protein therapeutics. Rotate injection sites to minimize.

Headache
UncommonMild

Reported in clinical trials. Usually self-resolving. Monitor frequency and severity.

Fatigue
UncommonMild

Reported in some trial participants. May be related to systemic effects of myostatin/activin inhibition or polycythemia.

Joint pain or stiffness
RareMild

Anecdotally reported in trials. Mechanism unclear; may relate to altered TGF-β signaling in connective tissue.

Cardiovascular events
RareSerious

Isolated cases reported in clinical trials. Polycythemia and altered hemodynamics may increase thrombotic or ischemic risk. Requires baseline and periodic cardiovascular assessment.

Dosing Reference

ParameterValue
Dose range1-3 mg/kg
Frequency, timing and route - members only

Research disclaimer

Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution Guide

Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution

Do not shake the vial vigorously; gentle swirling prevents peptide degradation

Discard immediately if the solution appears cloudy, discolored, or contains visible particles

Use within 30 days of reconstitution when stored at 2-8°C

Do not freeze the reconstituted solution; freezing may denature the peptide

Use the PeptideVolt reconstitution calculator for your exact concentration

Use the PeptideVolt reconstitution calculator for your exact concentration

Molecular and Pharmacological Data

Molecular weight110 kDa (approximately)
Half-life3-5 days (estimated from preclinical data; human half-life not definitively established due to trial discontinuation)

ACE-031 is a soluble ActRIIB receptor ectodomain that acts as a ligand trap, binding and sequestering myostatin and activin A—two TGF-β superfamily members that negatively regulate muscle growth. By removing these inhibitory signals, ACE-031 permits increased muscle protein synthesis and hypertrophy, particularly in conditions characterized by elevated myostatin or activin A signaling.

Pathways and mechanism detail available to members

Track your ACE-031 research

Free account. No credit card required.

Start Free

Browse the Research Library

40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.

View all peptides

Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. ACE-031 is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.